The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Other: Non-interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03331393

IM101-686

Details and patient eligibility

About

The purpose of this study is to investigate the value of Orencia in rapidly progressing Rheumatoid Arthritis (RA).

Enrollment: 265 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age at enrollment
• Confirmed diagnosed with RA
• Initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab with a record of the start date at the practice site

Exclusion criteria

• Does not have at least 1 or more poor RA prognostic factor: Evidence of joint erosions, Positive anti-CCP autoantibodies, Positive RF autoantibodies, Increased CRP levels, Increased ESR levels
• Was followed at the site for less than 1 year since biologic treatment initiation
• Patients with autoimmune diseases: Crohn's, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, anal fistula

Other protocol defined inclusion/exclusion criteria could apply

Trial design

265 participants in 2 patient groups

RA patients treated with Abatacept

Description:

Treated with Abatacept as a first-line biologic

Treatment:

Other: Non-interventional

RA patients treated with TNFi

Description:

Treated with Tumor necrosis factor inhibitor (TNFi) as a first-line biologic

Treatment:

Other: Non-interventional